ES cell biopsy from blastocyst.
Filed under: Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, adult stem cell, spinal cord injury, stem cells | Tagged: Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues | No Comments »
Athersys and their cardiac parter, Angiotech, announced today that they got the ok from the FDA to begin a Phase I clinical study using Athersys’ Multistem adult stem cell product in acute myocardial infarction (MI). This is the second IND approval for Athersys in just over a month (and a welcome Christmas present for [...]
Filed under: Angiotech, Athersys, Biomaterials, Clinical Trials, Joint Ventures, Regenerative Medicine, cardiac regeneration, cell delivery | Tagged: Angiotech, Athersys, cardiac cell therapy, cell delivery, IND | No Comments »
On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will start an open label, dose escalation trial to test their cells after bone marrow transplantation.
This [...]
Filed under: Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, adult stem cell, stem cells | Tagged: adult stem cells, Athersys, business model, stem cells clinical trials | 1 Comment »
